Apollo Hospitals earns HDFC Securities Buy; target raised to ₹10,000 after Q1

HDFC Securities retained its Buy rating on Apollo Hospitals after June-quarter revenue rose 21% and EBITDA grew 28%, citing momentum across hospitals, HealthCo and AHLL alongside ongoing capacity expansion.

By ·Devil's-advocate pass

Source published First seen Source NDTV Profit

The development

HDFC Securities reviewed Q1 performance across Indian companies. It retained a Buy on Apollo Hospitals, citing hospital, HealthCo and AHLL growth and capacity expansion; maintained Add on Max Financial; and raised Sansera’s target. Relaxo Footwears, Bata India and Eureka Forbes were also in focus.

The numbers

  • Apollo Hospitals target price: Rs 10,000, revised from Rs 9,680
  • Apollo Hospitals June-quarter revenue growth: 21%
  • Apollo Hospitals June-quarter EBITDA growth: 28%
  • Max Financial Services target price: Rs 1,765
  • Sansera Engineering target price: Rs 4,140, raised from Rs 3,382

Why it matters to operators and investors

Apollo Hospitals’ growth across core hospitals, HealthCo and AHLL supports continued investment in capacity and adjacent healthcare platforms.

What to watch next

  • Quarterly revenue and EBITDA growth versus the reported 21% and 28% June-quarter benchmarks.
  • Occupancy rates, ARPOB, payer mix and high-margin specialty volumes in core hospitals.
  • New-bed commissioning dates, ramp-up pace and capex intensity.
  • HealthCo and AHLL revenue growth, margins and evidence of cross-selling with hospital patients.
  • Net debt, interest costs and operating cash-flow conversion as expansion spending rises.
  • Competitive capacity additions and pricing behavior in major Indian metro markets.
  • Further analyst target revisions or consensus earnings upgrades following subsequent quarterly results.
  • Accelerate commissioning and ramp-up of announced hospital beds, especially in high-demand urban clusters.
  • Prioritize occupancy, average revenue per occupied bed and specialty-case mix to convert capacity expansion into EBITDA leverage.
  • Deepen HealthCo integration through pharmacy, diagnostics, digital follow-ups and discharge-to-home-care programs.
  • Use stronger earnings visibility to maintain investment in expansion while preserving balance-sheet flexibility.
  • Investors may rotate toward hospital operators with visible bed pipelines and integrated healthcare ecosystems, raising peer valuation sensitivity to quarterly occupancy and margin data.